

RANK ligand as a potential target for breast cancer prevention

Nature Medicine

22, 933-939

DOI: [10.1038/nm.4118](https://doi.org/10.1038/nm.4118)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Patient-derived xenograft (PDX) models in basic and translational breast cancer research. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 547-573.	2.7	189
2	RANKL/RANK: from bone loss to the prevention of breast cancer. <i>Open Biology</i> , 2016, 6, 160230.	1.5	53
3	RANKL Signaling and ErbB Receptors in Breast Carcinogenesis. <i>Trends in Molecular Medicine</i> , 2016, 22, 839-850.	3.5	15
4	Leveraging premalignant biology for immune-based cancer prevention. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 10750-10758.	3.3	57
5	Osteoporosis drug shows potential for breast cancer prevention. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 531-531.	21.5	0
6	RANKLing with breast cancer development. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 466-466.	12.5	1
7	Out-RANKing BRCA1 in Mutation Carriers. <i>Cancer Research</i> , 2017, 77, 595-600.	0.4	33
8	Translating Germline Cancer Risk into Precision Prevention. <i>Cell</i> , 2017, 168, 566-570.	13.5	22
9	Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort. <i>BMC Medicine</i> , 2017, 15, 26.	2.3	21
10	RE: Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	11
11	DNA repair and damage pathways in breast cancer development and therapy. <i>DNA Repair</i> , 2017, 54, 22-29.	1.3	76
12	Osteoclast inhibition in postmenopausal breast cancer: Is the evidence too strong to ignore?. <i>Cancer</i> , 2017, 123, 2392-2394.	2.0	3
13	Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	227
14	Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis. <i>Oncogene</i> , 2017, 36, 4527-4537.	2.6	23
15	Precancer Atlas to Drive Precision Prevention Trials. <i>Cancer Research</i> , 2017, 77, 1510-1541.	0.4	116
16	Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab. <i>Cell Cycle</i> , 2017, 16, 1022-1028.	1.3	19
17	Future cancer research priorities in the USA: a Lancet Oncology Commission. <i>Lancet Oncology</i> , The, 2017, 18, e653-e706.	5.1	153
18	The Role of Hereditary Factors in Ovarian Carcinoma. <i>Clinical Obstetrics and Gynecology</i> , 2017, 60, 728-737.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort. <i>Cancer Prevention Research</i> , 2017, 10, 525-534.	0.7	29
20	Enhanced Identification of Potential Pleiotropic Genetic Variants for Bone Mineral Density and Breast Cancer. <i>Calcified Tissue International</i> , 2017, 101, 489-500.	1.5	11
21	Osteoimmunology: The Conceptual Framework Unifying the Immune and Skeletal Systems. <i>Physiological Reviews</i> , 2017, 97, 1295-1349.	13.1	347
22	The nuclear factor-kappa B pathway and response to treatment in breast cancer. <i>Pharmacogenomics</i> , 2017, 18, 1697-1709.	0.6	31
23	Primary Immunoprevention of Epithelial Ovarian Carcinoma by Vaccination against the Extracellular Domain of Anti-Müllerian Hormone Receptor II. <i>Cancer Prevention Research</i> , 2017, 10, 612-624.	0.7	11
24	RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer. <i>Genes and Development</i> , 2017, 31, 2099-2112.	2.7	32
25	Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis. <i>Nature Communications</i> , 2017, 8, 15908.	5.8	118
26	Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 433-444.	1.1	31
27	Progesterone-Mediated Non-Classical Signaling. <i>Trends in Endocrinology and Metabolism</i> , 2017, 28, 656-668.	3.1	109
28	Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2011-2024.	1.2	30
29	Updates on the role of receptor activator of nuclear factor κ B/receptor activator of nuclear factor κ B ligand/osteoprotegerin pathway in breast cancer risk and treatment. <i>Current Opinion in Obstetrics and Gynecology</i> , 2017, 29, 4-11.	0.9	10
30	Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy. <i>Translational Oncology</i> , 2017, 10, 589-598.	1.7	17
31	Can we prevent BRCA1-associated breast cancer by RANKL inhibition?. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 11-16.	1.1	27
32	The RANK/RANKL/OPG system in tumorigenesis and metastasis of cancer stem cell: potential targets for anticancer therapy. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3801-3810.	1.0	57
33	Hereditary Pancreatic Cancer. , 2017, , .		0
34	Successful Treatment of Advanced Primary Cutaneous Apocrine Carcinoma on the Scrotum with Systemic Chemotherapy and Radiotherapy Followed by Denosumab. <i>Case Reports in Oncology</i> , 2017, 10, 52-56.	0.3	6
35	Immune response-associated gene profiling in Japanese melanoma patients using multi-omics analysis. <i>Oncology Reports</i> , 2017, 39, 1125-1131.	1.2	4
36	Pharmacological Inhibition of the Skeletal IKK β Reduces Breast Cancer-Induced Osteolysis. <i>Calcified Tissue International</i> , 2018, 103, 206-216.	1.5	8

#	ARTICLE	IF	CITATIONS
37	Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among <i>BRCA1</i> Mutation Carriers. <i>JAMA Oncology</i> , 2018, 4, 1059.	3.4	121
38	Physical activity during adolescence and young adulthood and the risk of breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 561-571.	1.1	25
39	The Current Landscape of 3D In Vitro Tumor Models: What Cancer Hallmarks Are Accessible for Drug Discovery?. <i>Advanced Healthcare Materials</i> , 2018, 7, 1701174.	3.9	66
40	The Role of Steroid Hormones in Breast and Effects on Cancer Stem Cells. <i>Current Stem Cell Reports</i> , 2018, 4, 81-94.	0.7	29
41	Update Breast Cancer 2018 (Part 2) – Advanced Breast Cancer, Quality of Life and Prevention. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 246-259.	0.8	23
42	Mechanisms of DNA damage repair in adult stem cells and implications for cancer formation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 89-101.	1.8	40
43	<i>RANKL</i> and <i>RANK</i> : From Mammalian Physiology to Cancer Treatment. <i>Trends in Cell Biology</i> , 2018, 28, 213-223.	3.6	72
44	Homology-Directed Repair and the Role of <i>BRCA1</i> , <i>BRCA2</i> , and Related Proteins in Genome Integrity and Cancer. <i>Annual Review of Cancer Biology</i> , 2018, 2, 313-336.	2.3	230
45	<i>NF-κB</i> at the Crossroads of Normal Mammary Gland Biology and the Pathogenesis and Prevention of <i>BRCA1</i> -Mutated Breast Cancer. <i>Cancer Prevention Research</i> , 2018, 11, 69-80.	0.7	10
46	The anti-tumor effect of <i>RANKL</i> inhibition in malignant solid tumors – A systematic review. <i>Cancer Treatment Reviews</i> , 2018, 62, 18-28.	3.4	103
47	Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study. <i>British Journal of Cancer</i> , 2018, 119, 1421-1427.	2.9	11
48	Epidemiology, Biology, Treatment, and Prevention of Ductal Carcinoma In Situ (DCIS). <i>JNCI Cancer Spectrum</i> , 2018, 2, pky063.	1.4	17
49	Chemoprevention in <i>BRCA1</i> mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment. <i>BMJ Open</i> , 2018, 8, e023115.	0.8	3
50	<i>BRCA</i> Mutations and Breast Cancer Prevention. <i>Cancers</i> , 2018, 10, 524.	1.7	71
51	<i>BRCA1</i> -Dependent Transcriptional Regulation: Implication in Tissue-Specific Tumor Suppression. <i>Cancers</i> , 2018, 10, 513.	1.7	13
52	Update Breast Cancer 2018 (Part 3) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1110-1118.	0.8	8
53	AACR White Paper: Shaping the Future of Cancer Prevention – A Roadmap for Advancing Science and Public Health. <i>Cancer Prevention Research</i> , 2018, 11, 735-778.	0.7	36
54	Circulating Receptor Activator of Nuclear Factor- κ B (<i>RANK</i>), <i>RANK</i> ligand (<i>RANKL</i>), and Mammographic Density in Premenopausal Women. <i>Cancer Prevention Research</i> , 2018, 11, 789-796.	0.7	9

#	ARTICLE	IF	CITATIONS
55	MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer. <i>Oncotarget</i> , 2018, 9, 33577-33588.	0.8	15
56	Roles of the RANKL-RANK axis in antitumour immunity – implications for therapy. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 676-693.	12.5	77
57	Cancer genetics, precision prevention and a call to action. <i>Nature Genetics</i> , 2018, 50, 1212-1218.	9.4	94
59	RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF- κ B activation and EGFR signaling. <i>Oncogene</i> , 2018, 37, 5101-5114.	2.6	22
60	Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 421-426.	1.1	10
61	Improved efficacy of mitochondrial disrupting agents upon inhibition of autophagy in a mouse model of BRCA1-deficient breast cancer. <i>Autophagy</i> , 2018, 14, 1214-1225.	4.3	33
62	Paracrine effect of regulatory T cells promotes cardiomyocyte proliferation during pregnancy and after myocardial infarction. <i>Nature Communications</i> , 2018, 9, 2432.	5.8	130
63	<i>Osteoimmunology</i> . , 2018, , 261-282.		1
64	Cancer Stem Cells, Bone and Tumor Microenvironment: Key Players in Bone Metastases. <i>Cancers</i> , 2018, 10, 56.	1.7	33
65	Mechanism of cytokinesis failure in ovarian cystadenomas with defective BRCA1 and P53 pathways. <i>International Journal of Cancer</i> , 2018, 143, 2932-2942.	2.3	6
66	Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1848.	1.8	5
67	The Vicious Cycle of Breast Cancer-Induced Bone Metastases, a Complex Biological and Therapeutic Target. <i>Current Molecular Biology Reports</i> , 2018, 4, 123-131.	0.8	5
68	Evidence of Intertissue Differences in the DNA Damage Response and the Pro-oncogenic Role of NF- κ B in Mice with Disengaged BRCA1-PALB2 Interaction. <i>Cancer Research</i> , 2018, 78, 3969-3981.	0.4	10
69	BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling. <i>Journal of Pathology</i> , 2018, 246, 41-53.	2.1	7
70	Sex-determining region Y (SRY) attributes to gender differences in RANKL expression and incidence of osteoporosis. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-16.	3.2	10
71	Mammary stem cells and progenitors: targeting the roots of breast cancer for prevention. <i>EMBO Journal</i> , 2019, 38, e100852.	3.5	69
72	Pregnancy and Breast Cancer: Pathways to Understand Risk and Prevention. <i>Trends in Molecular Medicine</i> , 2019, 25, 866-881.	3.5	54
73	Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm. <i>Medicina (Lithuania)</i> , 2019, 55, 415.	0.8	14

#	ARTICLE	IF	CITATIONS
74	A CD146 FACS Protocol Enriches for Luminal Keratin 14/19 Double Positive Human Breast Progenitors. <i>Scientific Reports</i> , 2019, 9, 14843.	1.6	11
75	BRCA1-associated R-loop affects transcription and differentiation in breast luminal epithelial cells. <i>Nucleic Acids Research</i> , 2019, 47, 5086-5099.	6.5	40
76	Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancer-induced bone loss. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1114-1124.	1.1	21
77	TRAF6 maintains mammary stem cells and promotes pregnancy-induced mammary epithelial cell expansion. <i>Communications Biology</i> , 2019, 2, 292.	2.0	14
78	Protein C receptor is a therapeutic stem cell target in a distinct group of breast cancers. <i>Cell Research</i> , 2019, 29, 832-845.	5.7	31
79	Osteoimmunology: evolving concepts in bone-immune interactions in health and disease. <i>Nature Reviews Immunology</i> , 2019, 19, 626-642.	10.6	402
81	RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2183.	1.8	22
82	BRCA1 Attenuates Progesterone Effects on Proliferation and NF- κ B Activation in Normal Human Mammary Epithelial Cells. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2019, 24, 257-270.	1.0	3
83	Germline Genetic Testing for Breast Cancer Risk: The Past, Present, and Future. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 61-74.	1.8	41
84	Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody. <i>Cancer Treatment Reviews</i> , 2019, 76, 57-67.	3.4	85
85	BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells. <i>Breast Cancer Research</i> , 2019, 21, 51.	2.2	16
86	PDGFR β stromal adipocyte progenitors transition into epithelial cells during lobulo-alveologenesis in the murine mammary gland. <i>Nature Communications</i> , 2019, 10, 1760.	5.8	37
87	Women's cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics. <i>Ecancermedicalsecience</i> , 2019, 13, 904.	0.6	12
88	Cationic liposome codelivering PI3K pathway regulator improves the response of BRCA1-deficient breast cancer cells to PARP1 inhibition. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 13037-13045.	1.2	9
89	BRCA1 and Breast Cancer: a Review of the Underlying Mechanisms Resulting in the Tissue-Specific Tumorigenesis in Mutation Carriers. <i>Journal of Breast Cancer</i> , 2019, 22, 1.	0.8	43
90	Translational highlights in breast cancer research and treatment: recent developments with clinical impact. <i>Current Opinion in Obstetrics and Gynecology</i> , 2019, 31, 67-75.	0.9	16
91	Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer. <i>Nature Communications</i> , 2019, 10, 766.	5.8	99
92	Cancer Cell-Derived Granulocyte-Macrophage Colony-Stimulating Factor Is Dispensable for the Progression of 4T1 Murine Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6342.	1.8	10

#	ARTICLE	IF	CITATIONS
93	BRCA1 mutation influences progesterone response in human benign mammary organoids. <i>Breast Cancer Research</i> , 2019, 21, 124.	2.2	15
94	Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas. <i>Breast Cancer Research</i> , 2019, 21, 132.	2.2	6
95	ERRÎ± promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors. <i>Oncogene</i> , 2019, 38, 950-964.	2.6	25
96	Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis. <i>Bone Research</i> , 2019, 7, 1.	5.4	72
97	Breast tumour organoids: promising models for the genomic and functional characterisation of breast cancer. <i>Biochemical Society Transactions</i> , 2019, 47, 109-117.	1.6	29
98	RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 12.	3.5	121
99	The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond. <i>Physiological Reviews</i> , 2019, 99, 115-160.	13.1	275
100	Progesterone receptor integrates the effects of mutated MED12 and altered DNA methylation to stimulate RANKL expression and stem cell proliferation in uterine leiomyoma. <i>Oncogene</i> , 2019, 38, 2722-2735.	2.6	36
101	Cancer immunoeediting and resistance to T cell-based immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 151-167.	12.5	1,093
102	Progesterone and Breast Cancer. <i>Endocrine Reviews</i> , 2020, 41, 320-344.	8.9	126
103	Stem Cells and the Differentiation Hierarchy in Mammary Gland Development. <i>Physiological Reviews</i> , 2020, 100, 489-523.	13.1	144
104	BRCA1/P53: Two strengths in cancer chemoprevention. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1873, 188339.	3.3	17
105	Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation. <i>Hereditary Cancer in Clinical Practice</i> , 2020, 18, 20.	0.6	3
106	The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7570.	1.8	19
107	Repurposing denosumab in breast cancer beyond prevention of skeletal related events: Could nonclinical data be translated into clinical practice?. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1235-1252.	1.3	1
108	Why is cancer so common a disease in people yet so rare at a cellular level?. <i>Medical Hypotheses</i> , 2020, 144, 110171.	0.8	3
109	RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2585-2597.	1.9	3
110	Targeting progesterone signaling prevents metastatic ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 31993-32004.	3.3	29

#	ARTICLE	IF	CITATIONS
111	Stresses in the metastatic cascade: molecular mechanisms and therapeutic opportunities. <i>Genes and Development</i> , 2020, 34, 1577-1598.	2.7	19
112	Targeting the RANKL/RANK/OPG Axis for Cancer Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 1283.	1.3	42
113	Management of women at increased risk for breast cancer secondary to high-risk proliferative lesions and family history of the disease. <i>Breast Journal</i> , 2020, 26, 1543-1548.	0.4	3
114	Stem Cell Determinant SOX9 Promotes Lineage Plasticity and Progression in Basal-like Breast Cancer. <i>Cell Reports</i> , 2020, 31, 107742.	2.9	34
115	NF- κ B in the New Era of Cancer Therapy. <i>Trends in Cancer</i> , 2020, 6, 677-687.	3.8	49
116	Repurposing denosumab in lung cancer beyond counteracting the skeletal related events: an intriguing perspective. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1331-1346.	1.4	5
117	Long-Term Evaluation of Women Referred to a Breast Cancer Family History Clinic (Manchester UK) <i>TJ ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>	1.7	12
118	Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. <i>Nature Communications</i> , 2020, 11, 6335.	5.8	46
119	Key steps for effective breast cancer prevention. <i>Nature Reviews Cancer</i> , 2020, 20, 417-436.	12.8	386
120	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 687-705.	12.5	178
121	RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women. <i>Scientific Reports</i> , 2020, 10, 5171.	1.6	5
122	Peripheral Blood-Based Biopsy for Breast Cancer Risk Prediction and Early Detection. <i>Frontiers in Medicine</i> , 2020, 7, 28.	1.2	24
123	Non-Surgical Cancer Risk Reduction in BRCA1 Mutation Carriers: Disabling the Remote Control. <i>Cancers</i> , 2020, 12, 547.	1.7	3
124	Not all cancers are created equal: Tissue specificity in cancer genes and pathways. <i>Current Opinion in Cell Biology</i> , 2020, 63, 135-143.	2.6	34
125	RANKL biology: bone metabolism, the immune system, and beyond. <i>Inflammation and Regeneration</i> , 2020, 40, 2.	1.5	241
126	Multifocal breast cancers are more prevalent in <i>BRCA2</i> versus <i>BRCA1</i> mutation carriers. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 146-153.	1.3	12
127	Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3022.	1.8	11
128	Osteoprotegerin: Relationship to Breast Cancer Risk and Prognosis. <i>Frontiers in Oncology</i> , 2020, 10, 462.	1.3	15

#	ARTICLE	IF	CITATIONS
129	Premenopausal Plasma Osteoprotegerin and Breast Cancer Risk: A Caseâ€“Control Analysis Nested within the Nurses' Health Study II. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1264-1270.	1.1	7
130	Nonsurgical Prevention Strategies in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Breast Care</i> , 2021, 16, 144-148.	0.8	19
131	Biological and genetic landscape of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). <i>European Journal of Surgical Oncology</i> , 2021, 47, 942-951.	0.5	13
132	BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188459.	3.3	5
133	Role of RANKL in cancer development and metastasis. <i>Journal of Bone and Mineral Metabolism</i> , 2021, 39, 71-81.	1.3	13
134	Inhibition of RANK signaling as a potential immunotherapy in breast cancer. <i>Oncolmmunology</i> , 2021, 10, 1923156.	2.1	3
135	Progestogens and Breast Cancer. , 2021, , 157-168.		0
136	Time-resolved single-cell analysis of Brca1 associated mammary tumourigenesis reveals aberrant differentiation of luminal progenitors. <i>Nature Communications</i> , 2021, 12, 1502.	5.8	34
137	RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 42.	2.2	11
138	Pathological Features of Tumors of the Nervous System in Hereditary Cancer Predisposition Syndromes: A Review. <i>Neurosurgery</i> , 2021, 89, 343-363.	0.6	3
139	Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development. <i>Npj Breast Cancer</i> , 2021, 7, 45.	2.3	7
140	Plasma Metabolome Signature Indicative of BRCA1 Germline Status Independent of Cancer Incidence. <i>Frontiers in Oncology</i> , 2021, 11, 627217.	1.3	4
141	Plasma Protein Biomarkers Associated with Higher Ovarian Cancer Risk in BRCA1/2 Carriers. <i>Cancers</i> , 2021, 13, 2300.	1.7	6
142	Estrogens and Progestogens in Triple Negative Breast Cancer: Do They Harm?. <i>Cancers</i> , 2021, 13, 2506.	1.7	17
143	Contraceptive progestins with androgenic properties stimulate breast epithelial cell proliferation. <i>EMBO Molecular Medicine</i> , 2021, 13, e14314.	3.3	20
144	Analyses of the association between breast cancer and osteoporosis/fracture history: a cross-sectional study using KoGES HEXA data. <i>Archives of Osteoporosis</i> , 2021, 16, 98.	1.0	1
145	SOX factors as cell-state regulators in the mammary gland and breast cancer. <i>Seminars in Cell and Developmental Biology</i> , 2021, 114, 126-133.	2.3	14
146	Microenvironmental control of cell fate decisions in mammary gland development and cancer. <i>Developmental Cell</i> , 2021, 56, 1875-1883.	3.1	12

#	ARTICLE	IF	CITATIONS
147	The Roadmap of RANKL/RANK Pathway in Cancer. <i>Cells</i> , 2021, 10, 1978.	1.8	29
148	Physical activity and Mediterranean diet as potential modulators of osteoprotegerin and soluble RANKL in gBRCA1/2 mutation carriers: results of the lifestyle intervention pilot study LIBRE-1. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 463-475.	1.1	1
149	Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes. <i>Cancer Letters</i> , 2021, 520, 255-266.	3.2	5
150	Promising agents on the horizon. , 2021, , 151-164.		0
151	Risk-Adjusted Prevention. Perspectives on the Governance of Entitlements to Benefits in the Case of Genetic (Breast Cancer) Risks. <i>Recent Results in Cancer Research</i> , 2021, 218, 47-66.	1.8	2
152	Aneuploidy and a deregulated DNA damage response suggest haploinsufficiency in breast tissues of <i>BRCA2</i> mutation carriers. <i>Science Advances</i> , 2020, 6, eaay2611.	4.7	27
153	90 YEARS OF PROGESTERONE: Progesterone receptor signaling in the normal breast and its implications for cancer. <i>Journal of Molecular Endocrinology</i> , 2020, 65, T81-T94.	1.1	36
154	Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Oncotarget</i> , 2016, 7, 86687-86694.	0.8	28
155	Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer. <i>Oncotarget</i> , 2017, 8, 3811-3825.	0.8	45
156	<i>BRCA1</i> haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells. <i>Oncotarget</i> , 2017, 8, 35019-35032.	0.8	12
157	Increased breast tissue receptor activator of nuclear factor- κ B ligand (RANKL) gene expression is associated with higher mammographic density in premenopausal women. <i>Oncotarget</i> , 2017, 8, 73787-73792.	0.8	12
158	Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma. <i>Oncotarget</i> , 2018, 9, 36126-36136.	0.8	62
159	Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Oncotarget</i> , 2019, 10, 2475-2483.	0.8	5
160	Expression of receptor activator of NF κ B (RANK) drives stemness and resistance to therapy in ER+HER2-breast cancer. <i>Oncotarget</i> , 2020, 11, 1714-1728.	0.8	15
161	Evolving insights: how DNA repair pathways impact cancer evolution. <i>Cancer Biology and Medicine</i> , 2020, 17, 805-827.	1.4	17
162	Histological Findings of Mammary Gland Development and Risk of Breast Cancer in <i>BRCA1</i> Mutant Mouse Models. <i>Journal of Breast Cancer</i> , 2021, 24, 455.	0.8	2
163	Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. <i>British Journal of Cancer</i> , 2022, 126, 302-309.	2.9	18
165	Transcription Factors as Detection and Diagnostic Biomarkers in Cancer. , 2017, , 31-58.		0

#	ARTICLE	IF	CITATIONS
166	Zukünftige Entwicklungen in der Bildgebung. , 2017, , 201-218.		0
168	Breast Cancer Prevention. , 2019, , 543-606.		0
171	Non-surgical prevention strategies in women with hereditary breast and ovarian cancer syndromes. Hormone Molecular Biology and Clinical Investigation, 2020, 41, .	0.3	5
172	The potential application of organoids in breast cancer research and treatment. Human Genetics, 2022, 141, 193-208.	1.8	11
173	Osteoclast Signal Transduction Pathways: The RANKL/RANK System. , 2020, , 200-220.		0
174	Young Age and Breast Cancer Biology. , 2020, , 13-22.		0
175	Translational Pharmacology in The Development of RANKL Inhibitors. , 2020, , 590-598.		0
176	RSPO2 and RANKL signal through LGR4 to regulate osteoclastic premetastatic niche formation and bone metastasis. Journal of Clinical Investigation, 2022, 132, .	3.9	30
177	Effects of menopausal hormone therapy-based on the role of estrogens, progestogens, and their metabolites in proliferation of breast cancer cells. Cancer Biology and Medicine, 2021, 18, 0-0.	1.4	0
181	Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology, 2022, 164, 514-521.	0.6	8
182	G-Quadruplex Matters in Tissue-Specific Tumorigenesis by BRCA1 Deficiency. Genes, 2022, 13, 391.	1.0	5
183	Delineating the role of osteoprotegerin as a marker of breast cancer risk among women with a BRCA1 mutation. Hereditary Cancer in Clinical Practice, 2022, 20, 14.	0.6	4
184	Novel insights linking BRCA1-IRIS role in mammary gland development to formation of aggressive PABCs: the case for longer breastfeeding.. American Journal of Cancer Research, 2022, 12, 396-426.	1.4	0
186	A human breast atlas integrating single-cell proteomics and transcriptomics. Developmental Cell, 2022, 57, 1400-1420.e7.	3.1	50
187	Beyond the pill: contraception and the prevention of hereditary ovarian cancer. Hereditary Cancer in Clinical Practice, 2022, 20, .	0.6	3
189	Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women. Genome Medicine, 2022, 14, .	3.6	10
190	Ductal keratin 15+ luminal progenitors in normal breast exhibit a basal-like breast cancer transcriptomic signature. Npj Breast Cancer, 2022, 8, .	2.3	7
191	Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management. International Journal of Molecular Sciences, 2022, 23, 7481.	1.8	12

#	ARTICLE	IF	CITATIONS
192	Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline Variants. <i>OncoTargets and Therapy</i> , 0, Volume 15, 815-826.	1.0	4
193	Breast surgery: a narrative review. <i>Medical Journal of Australia</i> , 2022, 217, 262-267.	0.8	2
194	Lessons from the Failure to Complete a Trial of Denosumab in Women With a Pathogenic <i>BRCA1/2</i> Variant Scheduling Risk-Reducing Salpingo-Oophorectomy. <i>Cancer Prevention Research</i> , 2022, 15, 721-726.	0.7	1
196	Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	3
197	RANKL and RANK in Cancer Therapy. <i>Physiology</i> , 2023, 38, 110-124.	1.6	1
198	The RANK/RANKL/OPG system and tumor bone metastasis: Potential mechanisms and therapeutic strategies. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	15
199	Inflammatory cytokine-enriched microenvironment plays key roles in the development of breast cancers. <i>Cancer Science</i> , 2023, 114, 1792-1799.	1.7	5
200	BRCA1 deficiency in mature CD8 ⁺ T lymphocytes impairs antitumor immunity. , 2023, 11, e005852.		4
201	RANK is a poor prognosis marker and a therapeutic target in ER ⁻ negative postmenopausal breast cancer. <i>EMBO Molecular Medicine</i> , 2023, 15, .	3.3	2
202	Differences between zoledronic acid and denosumab for breast cancer treatment. <i>Journal of Bone and Mineral Metabolism</i> , 2023, 41, 301-306.	1.3	3
203	Functional and Phenotypic Characterisations of Common Syngeneic Tumour Cell Lines as Estrogen Receptor-Positive Breast Cancer Models. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5666.	1.8	0
204	A View on Drug Development for Cancer Prevention. <i>Cancer Discovery</i> , 2023, 13, 1058-1083.	7.7	2
222	Cell origin of BRCA2-mutant breast cancer. <i>Nature Cell Biology</i> , 2024, 26, 43-44.	4.6	0